Friday, 13 Dec 2019

You are here

Ironwood Retreats from the US Gout Market

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

Ironwood is a 20-year-old pharmaceutical company, based out of Cambridge, MA, that is mainly known for developing linoclotide and other gastrointestinal intended therapies for irritable bowel syndrome with constipation and chronic constipation. The company started with the name  Microbia and later changed to Ironwood with new investors in 2008.

Ironwood had three FDA approved drugs: linaclotide (Linzess), for irritable bowel syndrome and constipation; and two gout drugs, lesinurad (Zurampic) and Duzallo. They acquired lesinurad from AstraZeneca in 2016.

Lesinurad was FDA approved in December 2015 and soon after by the EMA in February 2016.   But this came with safety concerns as hit had a boxed warning for renal failure, and the FDA required a postmarketing safety study.

AstraZeneca licensed lesinurad to Ironwood in 2016, but the agent as monotherapy (or co-therapy) never met marketing projections. Beyond the concerns over renal effects, several reports suggested the drug may not be effective as monotherapy. Even in combination (Duzallo) and FDA and EMA approval, there was low market uptake.  NICE in the UK denied the use of lesinurad in patients with hyperuricemia and gout.  

Between January and July 2018, Ironwoods research on lesinurads future potential in in select test markets failed to meet revenue expectations and Ironwood terminated its U.S. lesinurad license agreement with AstraZeneca.  This decision was projected to save Ironwood expects $75 to $100 million in 2019.

2018 sales revenues for lesinurad were north of $1.1 million. Ironwood obtained the US rights to AstraZeneca for $265 million - $100 million up front and up to $165 million more in milestones and royalties. AstraZeneca had acquired lesinurad (in development) in 2013 from Ardea Biosciences for $1.26 billion.

In the last quarter of 2018, Ironwood cut back its workforce by approximately 125 (mostly field-based sales) employees.  (Ironwood had previously reduced its workforce in January 2018 by approximately 60 field-based sales representatives.) 

On the company’s website they say, “If you have been taking either DUZALLO or ZURAMPIC to treat your condition, please consult with your healthcare professional before making any decisions to stop treatment. Please work with your healthcare professional for an alternate treatment for your condition.” And for any questions, please contact Ironwood via the Contact Us Webform (https://contactus.irwdpi.com/) or call the Ironwood Contact Center at 1-844-374-4793.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β).